WHAT IS CLAIMED IS:

1. A compound represented by Formula A:



A

or a pharmaceutically acceptable salt thereof, wherein:

R^1, R^2, R^3 and R^4 are each independently selected from the group consisting of: –H, -F, -Cl, -Br, -I, -CN, -OH, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl and C_{1-5}alkoxy,

wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl and C_{1-5}alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH, C_{1-8}alkoxy and -CO_2H,

and any two of R^1, R^2, R^3 and R^4 may be joined together with the atoms to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms optionally containing 1 or 2 oxygen atoms;

R^5 is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and C_{1-4}alkoxy,

wherein said C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and C_{1-4}alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-8}alkoxy;

R^6 is selected from the group consisting of : phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridizinyl and thienyl, each optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -CN, -OH, -NR^7R^8, -NO_2, phenyl, thienyl,

C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{3-6}cycloalkoxy, C_{1-4}alkylthio and C_{2-4}acyloxy,

wherein said phenyl, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{3-6}cycloalkoxy, C_{1-4}alkylthio and C_{1-4}acyloxy are each optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-8}alkoxy, and

R^6 may be substituted on two adjacent atoms to form a fused partially aromatic bicyclic ring of 9 to 12 atoms optionally containing one or two oxygen or sulfur groups, or both, and optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -CN, -OH, and C_{1-4}alkyl;

R^7 and R^8 are independently selected from the group consisting of: -H, C_{1-6}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy, and

R^7 and R^8 may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring is optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy;

U, **V** and **W** are independently selected from the group consisting of: –C(R^9)- and –N-;

each R^9 is independently selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and C_{1-4}alkoxy,

wherein said C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and C_{1-4}alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-8}alkoxy;

For **U** or **V**, R^9 and R^1 or R^9 and R^2 may be joined together with the atoms to which they are attached to form a 4 to 8 membered ring, optionally containing 1 or 2 oxygen, sulfur or N(R^{10})

atoms, thus forming a fused partially aromatic bicyclic ring system of 8 to 12 atoms with the 6-membered aromatic ring to which R^9 is attached;

X, **Y** and **Z** are independently selected from $-C(R^{11})=$, -O-, -N=, $-N(R^{12})-$ and -S- such that the resulting ring together with **Q** and **T** form an aromatic heterocycle;

Q and **T** are independently selected from  or , with the proviso that both **Q** and **T** are not  ;

R^{10}, R^{11} and R^{12} are each indepedently selected from the group consisting of : -H, C_{1-6}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy;

J is selected from the group consisting of: $-CO_2H$, $-PO_3H_2$, $-PO_2H_2$, $-SO_3H$, $-CONHSO_2R^{13}$, $-PO(R^{13})OH$,



; and

R^{13} is selected from the group consisting of: C_1-C_4 alkyl, phenyl, -CH_2OH and CH(OH)-phenyl; and

each R^{14} is independently selected from the group consisting of: -H and –CH_3.

2. A compound in accordance with Claim 1 represented by Formula I



I

or a pharmaceutically acceptable salt thereof, wherein:

R^1, R^2, R^3 and R^4 are each independently selected from the group consisting of: –H, -F, -Cl, -Br, -I, -CN, -OH, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl and C_{1-5}alkoxy,

wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl and C_{1-5}alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH, C_{1-8}alkoxy and $-CO_2H$,

and any two of R^1, R^2, R^3 and R^4 may be joined together with the atoms to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms optionally containing 1 or 2 oxygen atoms;

R^5 is selected from the group consisting of: -F, -Cl, -Br, -I, -CN, -OH, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and C_{1-4}alkoxy,

wherein said C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and C_{1-4}alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-8}alkoxy;

R^6 is selected from the group consisting of : phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridizinyl and thienyl, each optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -CN, -OH, $-NR^7R^8$, $-NO_2$, phenyl, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{3-6}cycloalkoxy, C_{1-4}alkylthio and C_{2-4}acyloxy,

wherein said phenyl, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy,

C_{3-6}cycloalkoxy, C_{1-4}alkylthio and C_{1-4}acyloxy are each optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-8}alkoxy, and

R^6 may be substituted on two adjacent atoms to form a fused partially aromatic bicyclic ring of 9 to 12 atoms optionally containing one or two oxygen or sulfur groups, or both, and optionally substituted with one to three substituents independently selected from the group consisting of: -F, -Cl, -Br, -I, -CN, -OH, and C_{1-4}alkyl;

R^7 and R^8 are independently selected from the group consisting of: -H, C_{1-6}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy, and

R^7 and R^8 may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring is optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy;

U, **V** and **W** are independently selected from the group consisting of: –C(R^9)- and –N-;

each R^9 is independently selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and C_{1-4}alkoxy,

wherein said C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and C_{1-4}alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-8}alkoxy;

For **U** or **V**, R^9 and R^1 or R^9 and R^2 may be joined together with the atoms to which they are attached to form a 4 to 8 membered ring, optionally containing 1 or 2 oxygen, sulfur or N(R^{10}) atoms, thus forming a fused partially aromatic bicyclic ring system of 8 to 12 atoms with the 6-membered aromatic ring to which R^9 is attached;

X, **Y** and **Z** are independently selected from –C(R^{11})=, -O-, -N=, -N(R^{12})- and -S- such that the resulting ring together with **Q** and **T** form an aromatic heterocycle;

Q and **T** are independently selected from  or  , with the proviso that both **Q** and **T** are not  ; and

R^{10}, R^{11} and R^{12} are each indepedently selected from the group consisting of : -H, C_{1-6}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy.

3. A compound according to Claim 2 wherein R^5 is methyl.

4. A compound according to Claim 2 wherein R^6 is selected from the group consisting of : phenyl and pyridinyl, each optionally substituted with one to three substituents independently selected from the group consisting of: F, -Cl, -Br, -I, -CN, -OH, $-NR^7R^8$, $-NO_2$, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkylthio, C_{3-6}cycloalkoxy and C_{1-4}acyloxy,

wherein said C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}alkylthio, C_{3-6}cycloalkoxy and C_{1-4}acyloxy are each optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-8}alkoxy; and

R^7 and R^8 are independently selected from the group consisting of: -H, C_{1-6}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl and C_{2-6}alkynyl are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy, and

R^7 and R^8 may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring is optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy.

5. A compound according to Claim 2 wherein **V** and **W** are –CH-.

6. A compound according to Claim 2 of Formula Ia



Ia

or a pharmaceutically acceptable salt thereof, wherein:

R^1 and R^2 are independently selected from the group consisting of: -H, -OH and methyl or R^1 and R^2 may be joined together with the atoms to which they are attached to form cyclopropyl;

U and **V** are each independently selected from the group consisting of: –C(R^9)- and –N-;

each R^9 is independently selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and C_{1-4}alkoxy, wherein said C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and C_{1-4}alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-8}alkoxy, and

For **U** or **V**, R^9 and R^1 or R^9 and R^2 may be joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the 6-membered aromatic ring to which R^9 is attached;

A is selected from the group consisting of: –N- and –C(R^{13})-, wherein R^{13} is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH_3, -OCH_3, -CF_3, ethynyl, -NO_2 and -NH_2;

R^a is selected from the group consisting of: NR^7R^8, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{3-6}cycloalkoxy, C_{1-4}alkylthio and C_{1-4}acyloxy, wherein said C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{3-6}cycloalkoxy, C_{1-4}alkylthio and C_{1-4}acyloxy are each optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: –F, -Cl, -Br, -I and -OH;

R^7 and R^8 are independently selected from the group consisting of: -H and C_{1-6}alkyl, optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy, and

R^7 and R^8 may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring is optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy; and

R^b is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH_3, -OCH_3, -CF_3, ethynyl, -NO_2 and -NH_2.

7. A compound according to Claim 2 of Formula Ib



Ib

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from the group consisting of: -H, -OH and methyl;

A is selected from the group consisting of: –N- and –C(R^{13})-, wherein R^{13} is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH_3, -OCH_3, -CF_3, ethynyl, -NO_2 and -NH_2;

R^a is selected from the group consisting of: NR^7R^8, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{3-6}cycloalkoxy, C_{1-4}alkylthio and C_{1-4}acyloxy, wherein said C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{3-6}cycloalkoxy, C_{1-4}alkylthio and C_{1-4}acyloxy are each optionally substituted from

one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: –F, -Cl, -Br, -I and -OH;

R^7 and R^8 are independently selected from the group consisting of: -H and C_{1-6}alkyl, optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy, and

R^7 and R^8 may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring is optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy; and

R^b is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, $-CH_3$, $-OCH_3$, $-CF_3$, ethynyl, $-NO_2$ and $-NH_2$.

8. A compound according to Claim 2 of Formula Ic



Ic

or a pharmaceutically acceptable salt thereof, wherein:

R^1 and R^2 are independently selected from the group consisting of: -H, -OH and methyl or R^1 and R^2 may be joined together with the atoms to which they are attached to form cyclopropyl;

U and V are each independently selected from the group consisting of: $-C(R^9)-$ and –N-;

each R^9 is independently selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and C_{1-4}alkoxy, wherein said C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and C_{1-4}alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-8}alkoxy, and

For **U** or **V**, R^9 and R^1 or R^9 and R^2 may be joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the 6-membered aromatic ring to which R^9 is attached;

A is selected from the group consisting of: –N- and –C(R^{13})-, wherein R^{13} is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH_3, -OCH_3, -CF_3, ethynyl, -NO_2 and -NH_2;

R^a is selected from the group consisting of: NR^7R^8, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{3-6}cycloalkoxy, C_{1-4}alkylthio and C_{1-4}acyloxy, wherein said C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{3-6}cycloalkoxy, C_{1-4}alkylthio and C_{1-4}acyloxy are each optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: –F, -Cl, -Br, -I and -OH;

R^7 and R^8 are independently selected from the group consisting of: -H and C_{1-6}alkyl, optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy, and

R^7 and R^8 may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring is optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy; and

R^b is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH_3, -OCH_3, -CF_3, ethynyl, -NO_2 and -NH_2.

9. A compound according to Claim 2 of Formula Id



Id

or a pharmaceutically acceptable salt thereof, wherein:

R^1 and R^2 are independently selected from the group consisting of: -H, -OH and methyl or R^1 and R^2 may be joined together with the atoms to which they are attached to form cyclopropyl;

U and **V** are each independently selected from the group consisting of: $-C(R^9)-$ and –N-;

each R^9 is independently selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -OH, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and C_{1-4}alkoxy, wherein said C_{1-4}alkyl, C_{1-4}alkenyl, C_{1-4}alkynyl and C_{1-4}alkoxy are each optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-8}alkoxy, and

R^9 and R^1 or R^9 and R^2 may be joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the 6-membered aromatic ring to which R^9 is attached;

A is selected from the group consisting of: –N- and $-C(R^{13})-$, wherein R^{13} is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, $-CH_3$, $-OCH_3$, $-CF_3$, ethynyl, $-NO_2$ and $-NH_2$;

R^a is selected from the group consisting of: NR^7R^8, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{3-6}cycloalkoxy, C_{1-4}alkylthio and C_{1-4}acyloxy, wherein said C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy, C_{3-6}cycloalkoxy, C_{1-4}alkylthio and C_{1-4}acyloxy are each optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: –F, -Cl, -Br, -I and -OH;

R^7 and R^8 are independently selected from the group consisting of: -H and C_{1-6}alkyl, optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy, and

R^7 and R^8 may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, optionally containing 1 or 2 oxygen atoms, said ring is optionally substituted with one to three substituents independently selected from the group consisting of: –F, -Cl, -Br, -I, -OH and C_{1-5}alkoxy; and

R^b is selected from the group consisting of: -H, -F, -Cl, -Br, -I, -CN, -CH_3, -OCH_3, -CF_3, ethynyl, -NO_2 and -NH_2.

10. A compound according to Claim 2 selected from the following table:



Ie

Ex.	R^a	R^b	A	U	R^2	R^1
1	*i*-PrO-	-CN	-CH=	=CH-	H	H
2	*i*-PrO-	Cl-	-CH=	=CH-	H	H
3	*i*-PrO-	Br-	-CH=	=CH-	H	H
4	*i*-PrO-	MeO-	-CH=	=CH-	H	H
5	*i*-PrO-	Me-	-CH=	=CH-	H	H
6	*i*-PrO-	F-	-CH=	=CH-	H	H
8	*i*-PrO-	-CF_3	-CH=	=CH-	R^2 and R^3 joined to form cyclopropyl	
9	*i*-PrO-	-CF_3	-CH=	=CH-	H	Me
10	*i*-PrO-	-CN	-CH=	=CH-	H	Me
11	*i*-PrO-	-CH3	-CH=	=CH-	H	Me
12	*i*-PrO-	-CF_3	-CH=	=CH-	Me	H
13	*i*-PrO-	-CN	-CH=	=CH-	Me	H
14	*i*-PrO-	-CH3	-CH=	=CH-	Me	H
15	*i*-PrO-	Cl-	-N=	=CH-	H	H
16	*i*-Pr-NH-	Cl-	-N=	=CH-	H	H
17	2,2,2-trifluoro-1-methylethoxy	Cl-	-N=	=CH-	H	H
18	pyrrolidinyl	Cl-	-N=	=CH-	H	H
19	morpholin-4-yl	Cl-	-N=	=CH-	H	H
20	*i*-Pr-N(Me)-	Cl-	-N=	=CH-	H	H

21	2,2,2-trifluoroethoxy	Cl-	-N=	=CH-	Me	H
22	2,2,2-trifluoro-1-methylethoxy	Cl-	-N=	=CH-	Me	H
23	3,3-difluoro piperidinyl	Cl-	-N=	=CH-	Me	H
24	3,3,-difluoro pyrrolidinyl	Cl-	-N=	=CH-	Me	H
25	morpholin-4-yl	$-CF_3$	-N=	=CH-	Me	H
26	3,3,-difluoro pyrrolidinyl	Cl-	-N=	=CH-	R^2 and R^3 joined to form cyclopropyl	
27	2,2,2-trifluoroethoxy	Cl-	-N=	=CH-	R^2 and R^3 joined to form cyclopropyl	
28	2,2,2-trifluoro-1-methylethoxy	Cl-	-N=	=CH-	R^2 and R^3 joined to form cyclopropyl	
29	1-Me-*n*-PrO-	Cl-	-N=	=CH-	R^2 and R^3 joined to form cyclopropyl	
30	*i*-PrO-	Cl-	-N=	=CH-	R^2 and R^3 joined to form cyclopropyl	
31	*i*-Bu-	Cl-	-N=	=CH-	H	H
32	*i*-Pr-N(Me)-	I-	-N=	=CH-	H	H
33	*i*-Pr-N(Me)-	-CN	-N=	=CH-	H	H
34	3,3,-difluoro pyrrolidinyl	I	-N=	=CH-	H	H
35	3,3,-difluoro pyrrolidinyl	-CN	-N=	=CH-	H	H
36	*i*-PrO-	-CN	-CH=	=CH-	R^2 and R^3 joined to form cyclopropyl	
37	2,2,2-trifluoro-1-methylethoxy	-CN	-CH=	=CH-	R^2 and R^3 joined to form cyclopropyl	
38	*i*-PrO-	MeO-	-CH=	=CH-	R^2 and R^3 joined to form cyclopropyl	
39	2,2,2-trifluoroethoxy	-CN	-CH=	=CH-	R^2 and R^3 joined to form cyclopropyl	
40	2,2,2-trifluoro-	-CN	-CH=	=CH-	R^2 and R^3 joined to	

	1-trifluoromethyl ethoxy				form cyclopropyl	
43	1-Me-*n*-PrO-	-CN	-CH=	=CH-	R^2 and R^3 joined to form cyclopropyl	
44	2,2,2-trifluoro-1-methylethoxy	-CN	-N=	=CH-	R^2 and R^3 joined to form cyclopropyl	
45	*i*-PrO-	I	-N=	=CH-	R^2 and R^3 joined to form cyclopropyl	
48	Ethoxy	-CN	-N=	=CH-	H	H
49	2,2,2-trifluoro-1-methylethoxy	-CN	-N=	=CH-	H	H
50	2-Me-*n*-Pr-	-CN	-N=	=CH-	H	H
51	2-methyl-1,1-difluoro-*n*-propyl	H	-CH=	=CH-	H	H
52	2,2,2-trifluoro-1-methylethoxy	I-	-N=	=CH-	H	H
53	Cyclopentyloxy	Cl-	-CH=	=CH-	H	H
54	2-Me-*n*-PrO-	Cl-	-CH=	=CH-	H	H
55	2,2,2-trifluoro-1-methylethoxy	-CN	-CH=	=CH-	H	H
56	2,2,2-trifluoro-1-methylethoxy	Cl-	-CH=	=CH-	H	H
57	*i*-PrO-	Cl-	-C(Cl)=	=CH-	H	H
58	cyclopropylmethoxy	Cl-	-CH=	=CH-	H	H
60	2,2,2-trifluoro-1-methylethoxy	$-NO_2$	-CH=	=CH-	H	H
61	2,2,2-trifluoroethoxy	-CN	-CH=	=CH-	H	H
62	2,2,2-trifluoro-1-trifluoromethyl ethoxy	-CN	-CH=	=CH-	H	H
63	1-Me-*n*-PrO-	-CN	-CH=	=CH-	H	H
65	2,2,2-trifluoro-1-methylethoxy	$-NH_2$	-CH=	=CH-	H	H
66	1-Me-*n*-PrO-	-CN	-CH=	=CH-	Me	H

67	2,2,2-trifluoro-1-trifluoromethyl ethoxy	-CN	-CH=	=CH-	Me	H
68	2,2,2-trifluoroethoxy	-CN	-CH=	=CH-	Me	H
69	*i*-PrO-	-CN	-CH=	=N-	H	H
70	2,2,2-trifluoro-1-methylethoxy	-CN	-N=	=N-	H	H
71	2,2,2-trifluoroethoxy	-CN	-CH=	=N-	H	H
72	2,2,2-trifluoro-1-trifluoromethyl ethoxy	-CN	-CH=	=N-	H	H
73	2,2,2-trifluoroethoxy	-CN	-CH=	=N-	Me	H
74	2,2,2-trifluoro-1-methylethoxy	-CN	-N=	=N-	Me	H
75	*i*-PrO-	$-CF_3$	-CH=	=CH-	H	H
79	*i*-PrO-	-CN	-CH=	=CH-	OH	OH
80	*i*-PrO-	-CN	-CH=	=CH-	OH	OH

or a pharmaceutically acceptable salt of any of the compounds above.

11. A compound according to Claim 2 selected from the following table:

















or a pharmaceutically acceptable salt of any of the compounds above.

12. A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

13. The method according to Claim 12 wherein the immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: systemic lupus erythematosis, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy and asthma.

14. The method according to Claim 12 wherein the immunoregulatory abnormality is bone marrow or organ transplant rejection or graft-versus-host disease.

15. The method according to Claim 12 wherein the immunoregulatory abnormality is selected from the group consisting of: transplantation of organs or tissue, graft-versus-host diseases brought about by transplantation, autoimmune syndromes including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis, inflammatory and hyperproliferative skin diseases, psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, seborrhoeic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedemas, vasculitis, erythema, cutaneous eosinophilia, lupus erythematosus, acne, alopecia areata, keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer, scleritis, Graves' opthalmopathy, Vogt-Koyanagi-Harada syndrome, sarcoidosis, pollen allergies, reversible obstructive airway disease, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, chronic or inveterate asthma, late asthma and airway hyper-responsiveness, bronchitis, gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel diseases, inflammatory bowel diseases, necrotizing enterocolitis, intestinal lesions associated with thermal burns, coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, migraine, rhinitis, eczema, interstitial nephritis, Goodpasture's syndrome, hemolytic-uremic syndrome, diabetic nephropathy, multiple myositis, Guillain-Barre syndrome, Meniere's disease, polyneuritis, multiple neuritis, mononeuritis, radiculopathy, hyperthyroidism, Basedow's disease, pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, anerythroplasia, osteoporosis, sarcoidosis, fibroid lung, idiopathic interstitial pneumonia, dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity, cutaneous T cell lymphoma, arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, myocardosis, scleroderma, Wegener's granuloma, Sjogren's syndrome, adiposis, eosinophilic fascitis, lesions of gingiva, periodontium, alveolar bone, substantia ossea dentis, glomerulonephritis, male pattern alopecia or alopecia senilis by preventing epilation or providing hair germination and/or promoting hair generation and hair growth, muscular dystrophy, pyoderma and Sezary's

syndrome, Addison's disease, ischemia-reperfusion injury of organs which occurs upon preservation, transplantation or ischemic disease, endotoxin-shock, pseudomembranous colitis, colitis caused by drug or radiation, ischemic acute renal insufficiency, chronic renal insufficiency, toxinosis caused by lung-oxygen or drugs, lung cancer, pulmonary emphysema, cataracta, siderosis, retinitis pigmentosa, senile macular degeneration, vitreal scarring, corneal alkali burn, dermatitis erythema multiforme, linear IgA ballous dermatitis and cement dermatitis, gingivitis, periodontitis, sepsis, pancreatitis, diseases caused by environmental pollution, aging, carcinogenesis, metastasis of carcinoma and hypobaropathy, disease caused by histamine or leukotriene-C_4 release, Behcet's disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, partial liver resection, acute liver necrosis, necrosis caused by toxin, viral hepatitis, shock, or anoxia, B-virus hepatitis, non-A/non-B hepatitis, cirrhosis, alcoholic cirrhosis, hepatic failure, fulminant hepatic failure, late-onset hepatic failure, "acute-on-chronic" liver failure, augmentation of chemotherapeutic effect, cytomegalovirus infection, HCMV infection, AIDS, cancer, senile dementia, trauma, and chronic bacterial infection.

16. The method according to Claim 12 wherein the immunoregulatory abnormality is selected from the group consisting of:

1) multiple sclerosis,
2) rheumatoid arthritis,
3) systemic lupus erythematosus,
4) psoriasis,
5) rejection of transplanted organ or tissue,
6) inflammatory bowel disease,
7) a malignancy of lymphoid origin,
8) acute and chronic lymphocytic leukemias and lymphomas and
9) insulin and non-insulin dependent diabetes.

17. A method of suppressing the immune system in a mammalian patient in need of immunosuppression comprising administering to said patient an immunosuppressing effective amount of a compound of Claim 1.

18. A pharmaceutical composition comprised of a compound in accordance with Claim 1 in combination with a pharmaceutically acceptable carrier.

19. A method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said respiratory disease or condition.

20. The method according to Claim 19 wherein the respiratory disease or condition is selected from the group consisting of: asthma, chronic bronchitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, infant respiratory distress syndrome, cough, eosinophilic granuloma, respiratory syncytial virus bronchiolitis, bronchiectasis, idiopathic pulmonary fibrosis, acute lung injury and bronchiolitis obliterans organizing pneumonia.

21. A method for treating a disease or condition related to vascular integrity in a patient in need thereof, wherein the disease or condition is selected from the group consisting of: angioedemas, vasculitis, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel diseases, inflammatory bowel diseases, necrotizing enterocolitis, intestinal lesions associated with thermal burns, arteriosclerosis, athersosclerosis, aortitis syndrome, ischemia-reperfusion injury of organs which occurs upon preservation, transplantation or ischemic disease, endotoxin-shock, pseudomembranous colitis, colitis caused by drug or radiation, ischemic acute renal insufficiency, chronic renal insufficiency, toxinosis caused by lung-oxygen or drugs, sepsis, pancreatitis, disease caused by histamine or leukotriene-C4 release, necrosis cuased by toxin, viral hepatitis, shock or anoxia, senile dementia, and trauma, comprising administering to the patient a compound in accordance with Claim 1 in an amount that is effective to treat the disease or condition.

22. A method for treating a disease or condition associated with cerebral or pulmonary edema in a patient in need thereof, comprising administering to the patient a compound in accordance with Claim 1 in an amount that is effective to treat the disease or condition.

23. A method according to Claim 22 wherein the disease or condition is selected from the group consisting of: shock, sepsis, acute respiratory distress syndrome and brain edema.

24. A compound according to Claim 1 of Formula If:



If

or a pharmaceutically acceptable salt thereof, wherein:

R^1 and R^2 are -H, or R^1 and R^2 may be joined together with the atoms to which they are attached to form cyclopropyl;

U and V are $-C(R^9)-$;

each R^9 is -H, or

For U or V, R^9 and R^1 or R^9 and R^2 may be joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the phenyl ring to which R^9 is attached;

R^a is selected from the group consisting of: C_{1-4}alkoxy and C_{3-6}cycloalkoxy, said C_{1-4}alkoxy and C_{3-6}cycloalkoxy groups optionally substituted from one up to the maximum number of substitutable positions with fluoro; and

R^b is selected from the group consisting of: C_{1-4}alkyl and C_{2-4}alkenyl.

25. A compound according to Claim 24 selected from the group consisting of:





or a pharmaceutically acceptable salt of any of the above.

26. A compound according to Claim 1 of Formula Ig:



Ig

or a pharmaceutically acceptable salt thereof, wherein:

A is selected from –N- or –CH-;

the group  is selected from the group consisting of:



;

R^1 and R^2 are -H, or R^1 and R^2 may be joined together with the atoms to which they are attached to form cyclopropyl;

U and **V** are $-C(R^9)-$;

each R^9 is -H, or

For **U** or **V**, R^9 and R^1 or R^9 and R^2 may be joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the phenyl ring to which R^9 is attached;

R^a is selected from the group consisting of: thienyl, NR^7R^8, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy and C_{3-6}cycloalkoxy, wherein said C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy and C_{3-6}cycloalkoxy are each optionally substituted from one up to the maximum number of substitutable positions with fluoro;

R^7 and R^8 are independently selected from the group consisting of: -H and C_{1-6}alkyl, optionally substituted with one to three flouro groups, and

R^7 and R^8 may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, said ring is optionally substituted with one to three fluoro groups.

27. A compound according to Claim 26 selected from the group consisting of:









or a pharmaceutically acceptable salt of any of the above.

28. A compound according to Claim 1 of Formula Ih:



Ih

or a pharmaceutically acceptable salt thereof, wherein:

A is selected from –N- or –CH-;

the group  is selected from the group consisting of:








;

R^1 and R^2 are -H, or R^1 and R^2 may be joined together with the atoms to which they are attached to form cyclopropyl;

R^5 is –H or $–CH_3$;

U and **V** are $–C(R^9)–$;

each R^9 is -H, or

For **U** or **V**, R^9 and R^1 or R^9 and R^2 may be joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the phenyl ring to which R^9 is attached;

R^a is selected from the group consisting of: -F, NR^7R^8, C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy and C_{3-6}cycloalkoxy, wherein said C_{1-4}alkyl, C_{3-6}cycloalkyl, C_{1-4}alkoxy and C_{3-6}cycloalkoxy

are each optionally substituted from one up to the maximum number of substitutable positions with fluoro;

R^7 and R^8 are independently selected from the group consisting of: -H and C_{1-6}alkyl, optionally substituted with one to three flouro groups, and

R^7 and R^8 may be joined together with the nitrogen atom to which they are attached to form a saturated monocyclic ring of 3 to 8 atoms, said ring is optionally substituted with one to three fluoro groups;

R^b is Cl or I;

J is selected from the group consisting of: $-CO_2H$, $-PO_3H_2$, $-PO_2H_2$, $-SO_3H$, $-CONHSO_2R^{13}$, $-PO(R^{13})OH$,





;

R^{13} is selected from the group consisting of: C_1-C_4 alkyl, phenyl, -CH_2OH and CH(OH)-phenyl; and

each R^{14} is independently selected from the group consisting of: -H and –CH_3.

29. A compound according to Claim 28, wherein:

For **U**, R^9 and R^1 are joined together with the atoms to which they are attached to form a 5 membered ring, thus forming a fused partially aromatic bicyclic ring system of 9 atoms with the phenyl ring to which R^9 is attached;

R^5 is CH_3;

R^b is Cl; and

J is selected from the group consisting of: -CO_2H,



, wherein each R^{14} is independently selected from the group consisting of: -H and –CH_3.

30. A compound according to Claim 28 selected from the group consisting of:











or a pharmaceutically acceptable salt of any of the above.